当前位置: 首页 >> 检索结果
7289. Parenting in a time of COVID-19.
作者: Lucie Cluver.;Jamie M Lachman.;Lorraine Sherr.;Inge Wessels.;Etienne Krug.;Sabine Rakotomalala.;Stephen Blight.;Susan Hillis.;Gretchen Bachman.;Ohad Green.;Alex Butchart.;Mark Tomlinson.;Catherine L Ward.;Jennifer Doubt.;Kerida McDonald.
来源: Lancet. 2020年395卷10231期e64页 7295. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
作者: Michael S Hofman.;Nathan Lawrentschuk.;Roslyn J Francis.;Colin Tang.;Ian Vela.;Paul Thomas.;Natalie Rutherford.;Jarad M Martin.;Mark Frydenberg.;Ramdave Shakher.;Lih-Ming Wong.;Kim Taubman.;Sze Ting Lee.;Edward Hsiao.;Paul Roach.;Michelle Nottage.;Ian Kirkwood.;Dickon Hayne.;Emma Link.;Petra Marusic.;Anetta Matera.;Alan Herschtal.;Amir Iravani.;Rodney J Hicks.;Scott Williams.;Declan G Murphy.; .
来源: Lancet. 2020年395卷10231期1208-1216页
Conventional imaging using CT and bone scan has insufficient sensitivity when staging men with high-risk localised prostate cancer. We aimed to investigate whether novel imaging using prostate-specific membrane antigen (PSMA) PET-CT might improve accuracy and affect management.
7296. Mass gathering events and reducing further global spread of COVID-19: a political and public health dilemma.
作者: Brian McCloskey.;Alimuddin Zumla.;Giuseppe Ippolito.;Lucille Blumberg.;Paul Arbon.;Anita Cicero.;Tina Endericks.;Poh Lian Lim.;Maya Borodina.; .
来源: Lancet. 2020年395卷10230期1096-1099页 7298. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.
作者: James M Chamberlain.;Jaideep Kapur.;Shlomo Shinnar.;Jordan Elm.;Maija Holsti.;Lynn Babcock.;Alex Rogers.;William Barsan.;James Cloyd.;Daniel Lowenstein.;Thomas P Bleck.;Robin Conwit.;Caitlyn Meinzer.;Hannah Cock.;Nathan B Fountain.;Ellen Underwood.;Jason T Connor.;Robert Silbergleit.; .; .
来源: Lancet. 2020年395卷10231期1217-1224页
Benzodiazepine-refractory, or established, status epilepticus is thought to be of similar pathophysiology in children and adults, but differences in underlying aetiology and pharmacodynamics might differentially affect response to therapy. In the Established Status Epilepticus Treatment Trial (ESETT) we compared the efficacy and safety of levetiracetam, fosphenytoin, and valproate in established status epilepticus, and here we describe our results after extending enrolment in children to compare outcomes in three age groups.
|